CLEVELAND, Oct. 15, 2020 /PRNewswire/ -- ViewRay, Inc.
(Nasdaq: VRAY) announced today details relating to the release of
its third quarter 2020 financial results.
ViewRay will hold a conference call to discuss results on
Thursday, November 5, 2020 at
4:30 p.m. ET / 1:30 p.m. PT. The dial-in numbers are (844)
277-1426 for domestic callers and (336) 525-7129 for international
callers. The conference ID number is 9819479. A live webcast of the
conference call will be available on the investor relations page of
ViewRay's corporate website at
http://investors.viewray.com/events-and-presentations/upcoming-events.
After the live webcast, a replay will remain available online on
the investor relations page of ViewRay's website, under "Financial
Events and Webinars", for 14 days following the call. In addition,
a telephonic replay of the call will be available until
November 12, 2020. The replay dial-in
numbers are (855) 859-2056 for domestic callers and (404) 537-3406
for international callers. Please use the conference ID number
9819479.
About ViewRay®
ViewRay, Inc. (Nasdaq: VRAY), designs,
manufactures, and markets the MRIdian® MR-Guided Radiation Therapy
System. MRIdian is built upon a proprietary high-definition MR
imaging system designed from the ground up to address the unique
challenges and clinical workflow for advanced radiation oncology.
Unlike MR systems used in diagnostic radiology, MRIdian's
high-definition MR was purpose-built to address specific
challenges, including beam distortion, skin toxicity, and other
concerns that potentially may arise when high magnetic fields
interact with radiation beams. ViewRay and MRIdian are registered
trademarks of ViewRay, Inc.
Forward-Looking Statements
This press release
contains forward-looking statements within the meaning of Section
27A of the Private Securities Litigation Reform Act. Statements in
this press release that are not purely historical are
forward-looking statements. Such forward-looking statements
include, among other things, the rate of new orders, upgrades, and
installations, ViewRay's anticipated future operating and financial
performance, and ViewRay's conference calls to discuss its
quarterly results. Actual results could differ from those projected
in any forward-looking statements due to numerous factors. Such
factors include, among others, the ability to commercialize MRIdian
Linac System, demand for ViewRay's products, the ability to convert
backlog into revenue, the timing of delivery of ViewRay's products,
the timing, length, and severity of the recent COVID-19
(coronavirus) pandemic, including its impacts across our businesses
on demand, operations and our global supply chains, the results and
other uncertainties associated with clinical trials, the ability to
raise the additional funding needed to continue to pursue ViewRay's
business and product development plans, the inherent uncertainties
associated with developing new products or technologies,
competition in the industry in which ViewRay operates, and overall
market conditions. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to ViewRay's business in general, see ViewRay's current
and future reports filed with the Securities and Exchange
Commission, including its Annual Report on Form 10-K for the fiscal
year ended December 31, 2019 and its
Quarterly Reports on Form 10-Q, as updated periodically with the
company's other filings with the SEC. These forward-looking
statements are made as of the date of this press release, and
ViewRay assumes no obligation to update the forward-looking
statements, or to update the reasons why actual results could
differ from those projected in the forward-looking statements,
except as required by law.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/viewray-announces-conference-call-for-third-quarter-2020-financial-results-to-be-held-after-market-on-november-5-2020-301152988.html
SOURCE ViewRay, Inc.